FDA warns of potential cardiovascular risk with Lexiva in HIV-infected patients - MPR
Links shared publicly online about this topic.
- 1,557total visits
FDA warns of potential cardiovascular risk with Lexiva in HIV-infected patients - MPR
empr.com —
The FDA and GlaxoSmithKline have notified healthcare professionals of a potential association between Lexiva (fosamprenavir calcium) and myocardial infarction and dyslipidemia in HIV-infected adults.
View full resource at empr.com
Tags: Heart Attack, HIV Medication, Mineral, Calcium, Healthcare, FDA, Lexiva, GlaxoSmithKline
Most Recently Shared on December 3, 2009 at 10:09 pm By:
MPR News: FDA warns of potential cardiovascular risk with Lexiva in HIV-infected patients: The FDA and GlaxoSmithKl... http://bit.ly/6eyGj4
Advertisement
